Literature DB >> 20584242

Health professionals' attitudes to depot injection antipsychotic medication: a systematic review.

C Besenius1, D Clark-Carter, P Nolan.   

Abstract

Healthcare professionals are key providers of information about antipsychotic medication and may have a significant influence on the decisions that service users make about how their medication is delivered. This systematic review aimed to explore health professionals' attitudes and beliefs towards antipsychotic depot medication. A systematic search of AMED, BNI, CINAHL, EMBASE, HEALTH BUSINESS ELITE, HMIC, MEDLINE and PsycINFO was carried out, as well as hand searches of journals and citation searches. Studies were selected if the terms 'attitudes/beliefs' and 'depot/injection' were included in the title or abstract, if health professionals were participants in the study and if original data were included. The search strategy produced 131 papers. Eight relevant studies were then selected for the review. They included six cross-sectional surveys and two qualitative studies. It was shown that the research carried out is still very sparse. Depots are seen as old fashioned, stigmatizing, causingside effects and being costly, and they are often not prescribed because of a presumed adherence to oral medication. More research needs to be carried out to further explore these issues, to look at the role of non-medical prescribers and explore the relationship between health professionals' attitudes and those of service users.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584242     DOI: 10.1111/j.1365-2850.2010.01550.x

Source DB:  PubMed          Journal:  J Psychiatr Ment Health Nurs        ISSN: 1351-0126            Impact factor:   2.952


  6 in total

1.  The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.

Authors:  Bawo O James; Joyce O Omoaregba; Kingsley M Okonoda; Edebi U Otefe; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

2.  Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Authors:  Matthias Kirschner; Anastasia Theodoridou; Paolo Fusar-Poli; Stefan Kaiser; Matthias Jäger
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

3.  Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.

Authors:  Heidi J Wehring; Sheryl Thedford; Maju Koola; Deanna L Kelly
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-01

Review 4.  Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia.

Authors:  Bernardo Carpiniello; Federica Pinna
Journal:  Drug Des Devel Ther       Date:  2016-05-24       Impact factor: 4.162

5.  Long acting injectable antipsychotics: Uninterrupted use during the COVID-19 pandemic.

Authors:  Maria Nystazaki; Maria Karanikola
Journal:  J Psychiatr Ment Health Nurs       Date:  2021-03-10       Impact factor: 2.720

6.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.